Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors

BACKGROUND: Monoclonal antibodies targeting programmed death ligand 1 (PD-L1) signaling currently approved for defective mismatch repair (dMMR)/microsatellite instability high (MSI-H) tumors must be delivered by intravenous infusion. Envafolimab, a humanized single-domain anti-PD-L1 antibody fused t...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jian, Deng, Yanhong, Zhang, Weijie, Zhou, Ai-Ping, Guo, Weijian, Yang, Jianwei, Yuan, Ying, Zhu, Liangjun, Qin, Shukui, Xiang, Silong, Lu, Haolan, Gong, John, Xu, Ting, Liu, David, Shen, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8218452/
https://www.ncbi.nlm.nih.gov/pubmed/34154614
http://dx.doi.org/10.1186/s13045-021-01095-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8218452/
https://www.ncbi.nlm.nih.gov/pubmed/34154614
http://dx.doi.org/10.1186/s13045-021-01095-1

Ejemplares similares